Berenberg Starts Ginkgo Bioworks Holdings Inc (DNA) at Buy

(Updated - November 28, 2022 4:03 PM EST)

Berenberg analyst Gaurav Goparaju initiates coverage on Ginkgo Bioworks Holdings Inc (NYSE: DNA) with a Buy rating and a price target of $6.00.

The analyst comments "We are initiating coverage of Ginkgo Bioworks (DNA) with a Buy rating and $6 price target, implying 245% upside. Ginkgo is leveraging its platform to industrialize synthetic biology at scale across diverse end-markets. Its platform maximizes the probabilities of success (PoS) of developing bioengineered products that are more sustainable, accessible, and of higher quality, all while realizing lower costs and faster timelines. With the only scaled horizontal platform in the space, we believe Ginkgo is well-positioned to disrupt cell programming across industries and become the primary developer of novel, synthetically engineered bioproducts."

For an analyst ratings summary and ratings history on Ginkgo Bioworks Holdings Inc click here. For more ratings news on Ginkgo Bioworks Holdings Inc click here.

Shares of Ginkgo Bioworks Holdings Inc closed at $1.99 yesterday.

You May Also Be Interested In

• RBC Capital Starts Inspire Medical Systems (INSP) at Outperform
• Sherwin-Williams (SHW) PT Lowered to $350 at Evercore ISI
• Jones Trading Starts Ellington (EFC) at Hold